Maranatha Gabaud, MD
Cardiovascular Disease · Silver Spring, MDNPI 1275988701
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,247 of the $4,844 with a category attached, or 67.0%. 29 manufacturers reported payments, led by Abbott at 46.6% of the total. Reporting peaked in 2022 at $2,280 and has fallen 70.1% since, to $681 in 2025.
Across 129 payments — averaging $37.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novartis$345
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$238
- Johnson & Johnson$217
- AstraZeneca$192
- Boston Scientific$182
- plus $1K from 23 others
What the payments were for
- Travel & lodging$1,37728%
- Food & beverage$3,24767%
- Education$2205%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $2,257 |
| Novartis | 18 | $345 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $238 |
| Johnson & Johnson | 8 | $217 |
| AstraZeneca | 9 | $192 |
| Boston Scientific | 4 | $182 |
| Actelion Pharmaceuticals US, Inc. | 4 | $156 |
| Pfizer | 7 | $149 |
| Merck | 8 | $133 |
| Novo Nordisk | 3 | $132 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Amgen | 3 | $78 |
| Baxter Healthcare | 3 | $74 |
| Medicomp Inc | 3 | $71 |
| Philips North America LLC | 3 | $61 |
| Lexicon Pharmaceuticals, Inc. | 3 | $58 |
| Inspire Medical Systems, Inc. | 1 | $42 |
| Boehringer Ingelheim | 2 | $42 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Bristol Myers Squibb | 1 | $23 |
| Vital Connect, Inc | 1 | $21 |
| Convatec Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,844 in reported general payments places this provider in the 70th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $72,389 |
| EntrestoSacubitril/Valsartan | 43 | $58,445 |
| JardianceEmpagliflozin | 37 | $38,738 |
| Repatha SureclickEvolocumab | 13 | $6,940 |
| Atorvastatin Calcium | 109 | $1,464 |
| Rosuvastatin Calcium | 52 | $1,146 |
| Nifedipine ErNifedipine | 23 | $647 |
| Chlorthalidone | 17 | $548 |
| Metoprolol Succinate | 54 | $497 |
| Amlodipine Besylate | 65 | $459 |
| Carvedilol | 17 | $428 |
| Spironolactone | 43 | $345 |
| Losartan Potassium | 35 | $274 |
| Furosemide | 45 | $207 |
| ClopidogrelClopidogrel Bisulfate | 16 | $194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $149 | $72,38948 claims |
| NovartisEntresto | $345 | $58,44543 claims |
| Boehringer IngelheimJardiance | $42 | $38,73837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Silver Spring
- Ellis UngerSilver Spring$23K
- Michael LincolnSilver Spring$14K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.